An article in the May 2007 issue of The Oncologist proposes a new system for handling skin toxicities associated with epidermal growth factor receptor (EGFR) inhibitors, an adverse reaction that ranges in type and severity and occurs in more than half of treated patients.
An article in the May 2007 issue of The Oncologist proposes a new system for handling skin toxicities associated with epidermal growth factor receptor (EGFR) inhibitors, an adverse reaction that ranges in type and severity and occurs in more than half of treated patients. According to the authors, all patients receiving the therapies should use a moisturizer and protect their skin against exposure to sunlight. Reactions that occur are classified as mild, moderate, or severe and based on the area of the rash, associated symptoms, and the risk of infection. Treatment is also targeted toward severity: mild steroids and/or antibiotics for mild reactions and stronger medications for moderate reactions. A reduction in the dose of EGFR inhibitor is recommended for a severe rash that hasn't cleared within two to four weeks of treatment. Once the rash has diminished, the EGFR inhibitor can be restarted. The article, "Epidermal Growth Factor (EGFR) Inhibitor-Associated Cutaneous Toxicities: An Evolving Paradigm in Clinical Management," can be accessed on-line at
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
Assessing Financial Impacts of Pharmacist-Led Interventions in Pediatric Ambulatory Care
December 5th 2023According to a poster abstract presented at the ASHP Midyear Clinical Meeting & Exhibition, specialty pharmacy services were used for a variety of conditions that have been reported in adult populations.